ArticleTranslational cancer research2025
Ubiquitin-specific peptidase 20 affects immune cell infiltration by regulating prostaglandin E2 on intraperitoneal metastasis model of colorectal cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ubiquitin-specific peptidase 20 (USP20) acts as oncogene or tumor suppressor gene in different types of cancer. But there are only a few reports about the effect of USP20 on colorectal cancer (CRC). This study aims to further explore the novel molecular mechanisms of USP20 in intraperitoneal metastasis of CRC. Methods: First, bioinformatics analyses were performed to discover the association between USP20 expression and the clinical characteristics of CRC. Subsequently, the mouse model was constructed using a USP20 knockout (USP20-KO) colon cell line to validate the effects of USP20 on intraperitoneal metastasis and immune cell infiltration. And then metabolomics study was performed on the USP20-KO cells to find the novel mechanisms of USP20. Finally, the relationship of prostaglandin E2 (PGE2) and USP20 was identified by enzyme-linked immunosorbent assay (ELISA) and Western blotting experiments. Results: Bioinformatics analyses showed that the USP20 expression was significantly upregulated in CRC and affected immune cell infiltration. The animal model study revealed that the intraperitoneal metastasis of tumor cell was inhibited by knocking out USP20, and the expression of USP20 could affect the proportions of CD8 Conclusions: The USP20 expression is significantly upregulated in CRC, and can promote tumor metastasis by affecting immune cell infiltration. As an important tumor metabolite which can influence immune cell infiltration, PGE2 is regulated by USP20 through the protein degradation of mPGES-1 and 15-PGDH mediated by proteasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.